Get In Touch with Klona Biotech
Please tell us a little bit about yourself and why you'd like to get connected. Klona Biotech + SOSV will follow up with you via email.
Klona Biotech is redefining reconstructive medicine with 3D-printed, personalized implants for mechanically demanding tissues like ligaments, tendons, and cartilage. Millions of patients each year require grafts for these tissues, yet donor shortages and graft failure remain major barriers to recovery.
Klona’s proprietary bioprinting platform integrates fiber-reinforced “gel-textile” composites – materials up to twenty times stronger than standard bioprints while remaining compatible with living cells. The result is regenerative implants that combine biological function with real mechanical strength.
Founded by Dylan Yeo (University of Oxford) and Thomas Groom (Imperial College London), Klona is developing its first ligament implant and next-generation printer system to enable hospitals to bioprint patient-specific tissues on demand.
Please tell us a little bit about yourself and why you'd like to get connected. Klona Biotech + SOSV will follow up with you via email.
No Offer, Solicitation, Advice, or Recommendation
Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.